Business Wire

CIRIUM

11.3.2021 07:27:13 CET | Business Wire | Press release

Share
Cirium Acquires Migacore a Travel Technology Start-up That Promises to Transform How Airlines Forecast Passenger Demand

Cirium , the aviation analytics company, which is part of RELX, today announces the acquisition of Migacore , a travel technology start-up that has demonstrated how applying advanced machine learning (ML) techniques to online data sources can help airlines stay ahead of changes in passenger demand.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210310006079/en/

Migacore has worked with some of the world’s most advanced carriers, such as Lufthansa and Singapore Airlines, to translate data from online news, search, social media, events and exhibitions, into signals that can help predict real-world travel demand.

After a series of successful airline trials, the Migacore team and technology are joining Cirium, which will help to scale the capabilities. The Migacore team will not only gain access to Cirium’s data and resources, but also to the group’s commercial reach across global aviation.

Airline demand models have traditionally been built around comparing current booking activity against historic trends, with the ticket offers raised or lowered to ensure that a flight is filled at optimum fare levels. The search was already on to improve on this but has been accelerated by the unprecedented collapse of flying during the pandemic.

“The airline industry has been experimenting with new sources of demand data for some time, but the pandemic has now made this an absolute necessity. Past booking patterns today give virtually no guide to current demand,” said Kevin O’Toole, chief strategy officer at Cirium.

“Migacore is not alone in looking for new demand signals, but it really stands out. Their airline partners were clearly impressed with how the team had taken time to understand and integrate with the highly automated workflow around Revenue Management. And we were impressed too,” said O’Toole.

“Integrating our forecasting capabilities into the Cirium portfolio will bring forward the new model that the market has needed for some time, allowing airlines to better forecast the intent to travel. Ultimately that means better matching between market demand and the airline offer, which should be good for travelers and carriers alike,” said Abheer Kolhatkar, chief executive officer and co-founder at Migacore.

The plan is to scale the existing service under the Cirium brand and to make similar forecasting available to clients across air travel and into aerospace, aircraft finance and beyond.

For further information please visit www.cirium.com and follow Cirium updates via LinkedIn and Twitter .

About Cirium

Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.

About RELX

RELX is a global provider of information-based analytics and decision tools for professional and business customers. The Group serves customers in more than 180 countries and has offices in about 40 countries. It employs over 33,000 people, of whom almost half are in North America. The shares of RELX PLC, the parent company, are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX. The market capitalisation is approximately £33.3bn, €39bn, $46.5bn.

About Migacore

Migacore is a tech start-up founded and built by machine learning experts, focusing on bringing predictive demand forecasting for airlines. Migacore was one of the first start-ups to join IAG’s Hangar 51 program, is an alumni of Accelerate@IATA — a program led by IATA and Silicon Valley’s platform Plug and Play—and was one of the first start-ups to graduate from Singapore Airline’s KrisLab scheme. Migacore’s innovation has been featured heavily at key industry events including ATPCO’s Elevate events 2019 and 2018 , Applied Machine Learning Days (AMLD) 2020 , Entrepreneur First 2017 and NDR – The Artificial Intelligence Conference 2018 , and was named as Plug and Play’s 11 start-ups to watch for 2020 .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye